14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today BIIB ranks #14427 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

$234.72 (3.48%)

Volume: 1M

Closed: Dec 08, 2021

Hollow Logo Score: -1.014

Biogen Inc. Stock Forecast

$234.72 (3.48%)

Volume: 1M

Closed: Dec 08, 2021

Score Hollow Logo -1.014
Which way will BIIB go? Request
Key Stats
P/E Ratio 21.55
Beta 0.32
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] RSI14 is 26 and the stock is currently not being overbought or oversold

Biogen Inc. stock price up 3.48% on Wednesday
(Updated on Dec 08, 2021)


Sell candidate since 2021-11-16 Loss -10.26%

The Biogen Inc. stock price gained 3.48% on the last trading day (Wednesday, 8th Dec 2021), rising from $226.83 to $234.72. , and has now gained 4 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the day the stock fluctuated 4.13% from a day low at $225.90 to a day high of $235.22. The price has fallen in 7 of the last 10 days and is down by -7.65% for this period. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 476 thousand more shares were traded than the day before. In total, 1 million shares were bought and sold for approximately $331.72 million.

The stock lies in the middle of a wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -20.29% during the next 3 months and, with a 90% probability hold a price between $176.01 and $204.51 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Signals & Forecast

A buy signal was issued from a pivot bottom point on Friday, December 03, 2021, and so far it has risen 4.82%. Further rise is indicated until a new top pivot has been found. Volume is rising along with the price. This is considered to be a good technical signal. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Biogen Inc. stock holds a buy signal from the short-term moving average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term moving average at $257.39. On a fall, the stock will find some support from the short-term average at $229.05. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD).

Support, Risk & Stop-loss

Biogen Inc. finds support from accumulated volume at $229.50 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $9.32 between high and low, or 4.13%. For the last week, the stock has had a daily average volatility of 2.76%.

Our recommended stop-loss: We hold an negative evaluation for this stock. No stop-loss is set.

Is Biogen Inc. stock A Buy?

Biogen Inc. holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

Current score: -1.014

Predicted Opening Price for Biogen Inc. of Thursday, December 9, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price December 9, 2021 Current price
$231.95 $234.72 (Overvalued)
Sell Candidate Unchanged

Remember To Visit Our YouTube Channel

Analyst Ratings

On Dec 08, 2021 "Wells Fargo & Company" gave "" rating for BIIB. The price target was set to $234.72+3.5%.

Volatility and Risk
Daily Average Volatility: 2.76 %
Overall Risk: Very High High Medium Low Very Low
Volatility
2.76 %
Daily Average Volatility
Overall Risk

Very High
High
Medium
Low
Very Low

Support & Resistance

Resistance: $235.74
Price: $234.72
Support: $229.50

BIIB Insider Trading Show all Trades

INSIDER POWER

1.905

Last 100 transactions
Buy: 157 423 | Sell: 82 641 (Shares)
Date Action Amount Person Type
Dec 03, 2021 Sell 265 Kramer Robin Restricted Stock Unit
Dec 03, 2021 Sell 104 Kramer Robin Restricted Stock Unit
Dec 03, 2021 Sell 74 Kramer Robin Restricted Stock Unit
Dec 03, 2021 Sell 22 Kramer Robin Common Stock
Dec 03, 2021 Sell 78 Kramer Robin Common Stock
Show all Insider Trades
INSIDER POWER

1.905

Last 100 transactions
Buy: 157 423 | Sell: 82 641 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 241.27 2.79 %
237.71 1.27 %
235.51 0.34 %
Current price: 234.72
Support 228.39 -2.70 %
226.19 -3.64 %
222.63 -5.15 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 266.57 13.57 %
236.11 0.59 %
235.74 0.43 %
Current price 234.72
Support 229.50 -2.22%
228.52 -2.64%
223.92 -4.60%

Click to get the best stock tips daily for free!

About Biogen Inc.

Biogen Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurodegenerative diseases, hematologic conditions, and autoimmune disorders. It offers TECFIDERA, AVONEX, and PLEGRIDY to treat relapsing forms of multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohn’s disease; and FAMPYRA to improve walking ability for patients with MS. The company also provides ELOCTATE to treat adults and children ... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT